Vaginal tolerance of CT based image-guided high-dose rate interstitial brachytherapy for gynecological malignancies

Naoya Murakami, Takahiro Kasamatsu, Minako Sumi, Ryoichi Yoshimura, Ken Harada, Mayuka Kitaguchi, Shuhei Sekii, Kana Takahashi, Kotaro Yoshio, Koji Inaba, Madoka Morota, Yoshinori Ito, Jun Itami, Naoya Murakami, Takahiro Kasamatsu, Minako Sumi, Ryoichi Yoshimura, Ken Harada, Mayuka Kitaguchi, Shuhei Sekii, Kana Takahashi, Kotaro Yoshio, Koji Inaba, Madoka Morota, Yoshinori Ito, Jun Itami

Abstract

Background: Purpose of this study was to identify predictors of vaginal ulcer after CT based three-dimensional image-guided high-dose-rate interstitial brachytherapy (HDR-ISBT) for gynecologic malignancies.

Methods: Records were reviewed for 44 female (14 with primary disease and 30 with recurrence) with gynecological malignancies treated with HDR-ISBT with or without external beam radiation therapy. The HDR-ISBT applicator insertion was performed with image guidance by trans-rectal ultrasound and CT.

Results: The median clinical target volume was 35.5 ml (2.4-142.1 ml) and the median delivered dose in equivalent dose in 2 Gy fractions (EQD2) for target volume D90 was 67.7 Gy (48.8-94.2 Gy, doses of external-beam radiation therapy and brachytherapy were combined). For re-irradiation patients, median EQD2 of D(2cc) for rectum and bladder, D0.5cc, D(1cc), D(2cc), D(4cc), D(6cc) and D(8cc) for vaginal wall was 91.1 Gy, 100.9 Gy, 260.3 Gy, 212.3 Gy, 170.1 Gy, 117.1 Gy, 105.2 Gy, and 94.7 Gy, respectively. For those without prior radiation therapy, median EQD2 of D(2cc) for rectum and bladder, D(0.5cc), D(1cc), D(2cc), D(4cc), D(6cc) and D(8cc) for vaginal wall was 56.3 Gy, 54.3 Gy, 147.4 Gy, 126.2 Gy, 108.0 Gy, 103.5 Gy, 94.7 Gy, and 80.7 Gy, respectively. Among five patients with vaginal ulcer, three had prior pelvic radiation therapy in their initial treatment and three consequently suffered from fistula formation. On univariate analysis, re-irradiation and vaginal wall D(2cc) in EQD2 was the clinical predictors of vaginal ulcer (p = 0.035 and p = 0.025, respectively). The ROC analysis revealed that vaginal wall D(2cc) is the best predictor of vaginal ulcer. The 2-year incidence rates of vaginal ulcer in the patients with vaginal wall D(2cc) in EQD2 equal to or less than 145 Gy and over 145 Gy were 3.7% and 23.5%, respectively, with a statistically significant difference (p = 0.026).

Conclusions: Re-irradiation and vaginal D(2cc) is a significant predictor of vaginal ulcer after HDR-ISBT for gynecologic malignancies. Three-dimensional image-guided treatment planning should be performed to ensure adequate target coverage while minimizing vaginal D(2cc) in order to avoid vagina ulcer.

Figures

Figure 1
Figure 1
Cumulative incidene of vaginal ulcer. a: Cumulative incidence of vaginal ulcer. b: Cumulative incidence of vaginal ulcer stratified by vaginal wall D2cc 145 Gy in EQD2.

References

    1. Martinez A, Cox RS, Edmundson GK. A multiple-site perineal applicator (MUPIT) for treatment of prostatic, anorectal, and gynecologic malignancies. Int J Radiat Oncol Biol Phys. 1984;10:297–305. doi: 10.1016/0360-3016(84)90016-6.
    1. Stock RG, Chan K, Terk M, Dewyngaert JK, Stone NN, Dottino P. A new technique for performing Syed-Neblett template interstitial implants for gynecologic malignancies using transrectal-ultrasound guidance. Int J Radiat Oncol Biol Phys. 1997;37:819–825. doi: 10.1016/S0360-3016(96)00558-5.
    1. Martinez A, Edmundson GK, Cox RS, Gunderson LL Howes AE. Combination of external beam irradiation and multiple-site perineal applicator (MUPIT) for treatment of locally advanced or recurrent prostatic, anorectal, and gynecologic malignancies. Int J Radiat Oncol Biol Phys. 1985;11:391–398. doi: 10.1016/0360-3016(85)90163-4.
    1. Erickson B, Albano K, Gillin M. CT-guided interstitial implantation of gynecologic malignancies. Int J Radiat Oncol Biol Phys. 1996;36:699–709. doi: 10.1016/S0360-3016(96)00373-2.
    1. Lee LJ, Damato AL, Viswanathan AN. Clinical outcomes of high-dose-rate interstitial gynecologic brachytherapy using real-time CT guidance. Brachytherapy. 2013;12:303–310. doi: 10.1016/j.brachy.2012.11.002.
    1. Georg P, Lang S, Dimopoulos JC. et al.Dose-volume histogram parameters and late side effects in magnetic resonance image-guided adaptive cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys. 2011;79:356–362. doi: 10.1016/j.ijrobp.2009.11.002.
    1. Lee LJ Viswanathan AN. Predictors of Toxicity After Image-guided High-dose-rate Interstitial Brachytherapy for Gynecologic Cancer. Int J Radiat Oncol Biol Phys. 2012;84:1192–1197. doi: 10.1016/j.ijrobp.2012.01.085.
    1. Bethesda M. ICRU report 38. Dose and volume specification for reporting intracavitary therapy in gynecology. International Commission on Radiation Units and Measurements. 1985;38:1–20.
    1. Itami J, Hara R, Kozuka T. et al.Transperineal high-dose-rate interstitial radiation therapy in the management of gynecologic malignancies. Strahlenther Onkol. 2003;179:737–741. doi: 10.1007/s00066-003-1069-1.
    1. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985;58:515–528. doi: 10.1259/0007-1285-58-690-515.
    1. Bentzen SM, Dorr W, Gahbauer R. et al.Bioloeffect modeling and effective dose concepts in radiation oncology – Terminology, quantities and units. Radiother Oncol. 2012;105:266–268. doi: 10.1016/j.radonc.2012.10.006.
    1. Fidarova EF, Berger D, Schussler S. et al.Dose volume parameter D2cc does not correlate with vaginal side effects in individual patients with cervical cancer treated within a defined treatment protocol with very high brachytherapy doses. Radiother Oncol. 2010;97:76–79. doi: 10.1016/j.radonc.2010.05.005.
    1. LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys. 1995;31:1049–1091.
    1. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96:644–647. doi: 10.1111/j.1651-2227.2006.00178.x.
    1. Samuel P, Perry W. Grigsby. The irradiation tolerance dose of the proximal vagina. Radiother Oncol. 2007;67:77–85.
    1. Potter R, Haie-Meder C, Van Limbergen E. et al.Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image based treatment planning in cervix cancer brachytherapy 3D dose volume parameters and aspects of 3D image based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78:67–77. doi: 10.1016/j.radonc.2005.11.014.
    1. Viswanathan AN, Thomadsen B. American Brachytherapy Society concensus guidelines for locally advanced carcinoma of the cervix. Part I: General principles. Brachytherapy. 2012;11:33–46. doi: 10.1016/j.brachy.2011.07.003.
    1. Dimopoulos JCA, Schmid MP, Fidarova E. et al.Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results. Int J Radiat Oncol Biol Phys. 2012;82:1880–1888. doi: 10.1016/j.ijrobp.2011.03.049.

Source: PubMed

3
구독하다